
|Articles|August 1, 2003
Moxifloxacin hastens resolution of bacterial conjunctivitis
Fort Lauderdale, FL-A 4-day course of moxifloxacin ophthalmic solution 0.5% (Vigamox, Alcon) is a safe and effective treatment for bacterial conjunctivitis in adults and children as young as 1 month old, according to results from a phase III FDA study, reported Harold R. Katz, MD, who spoke on behalf of the Moxifloxacin Conjunctivitis Study Group at the annual meeting of the Association for Research in Vision and Ophthalmology. The fourth-generation fluoroquinolone received FDA approval in April for the treatment of bacterial conjunctivitis (see related article, Ophthalmology Times, June 1, 2003 issue, Page 1).
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Eyes on May 2026: A month of durable therapies, a regulatory reversal, and rethought echanisms
2
Reasoning prompts sharpen multimodal AI on bilingual ophthalmology exam questions
3
TECNIS PureSee IOL launches in US following FDA approval for cataract surgery
4
Beyond the Walls: Leading with love, loyalty, and a team first philosophy with Vance Thompson, MD
5





















